Gastric Acid Suppressants May Up Risk of Recurrent C. difficile

Share this content:
Gastric Acid Suppressants May Up Risk of Recurrent <i>C. difficile</i>
Gastric Acid Suppressants May Up Risk of Recurrent C. difficile

MONDAY, March 27, 2017 (HealthDay News) -- Use of gastric acid suppressants may increase the risk of recurrent Clostridium difficile infection (CDI), according to a meta-analysis published online March 27 in JAMA Internal Medicine.

Raseen Tariq, M.B.B.S., from the Mayo Clinic in Rochester, Minn., and colleagues conducted a systematic review and meta-analysis to examine the correlation between gastric acid suppressants and recurrent CDI. Data were included from 16 observational studies, reporting 7,703 patients with CDI.

Overall, 19.8 percent of patients with CDI developed recurrent CDI. The researchers found that the rate of recurrent CDI was 22.1 and 17.3 percent among patients with and without gastric acid suppression, respectively, indicating an increased risk by meta-analysis (odds ratio, 1.52). Significant heterogeneity was seen among the studies ( = 64 percent). After adjustment for age and potential confounders, the increased risk of recurrent CDI with use of gastric acid suppressants was confirmed (odds ratio, 1.38).

"Meta-analyses of observational studies suggest that patients who receive gastric acid suppressants may be at increased risk for recurrent CDI," the authors write. "These data should be interpreted with caution because they may be confounded owing to the observational design of the individual studies."

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Incident Contrast Sensitivity Common in Middle-Aged Adults

Incident Contrast Sensitivity Common in Middle-Aged Adults

Factors linked to elevated risk include cadmium level in highest quintile, older age, more plaque sites

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Reduces all-cause mortality, cardiovascular-related hospitalizations compared with placebo

Scribes Improve Physician Workflow, Patient Interaction

Scribes Improve Physician Workflow, Patient Interaction

Scribes lower EHR documentation burden for doctors and increase time spent interacting with patients

is free, fast, and customized just for you!




Already a member?

Sign In Now »